Breast cancer, with its myriad subtypes, has long eluded a uniform treatment strategy. The disease’s molecular complexity has rendered traditional, blanket treatments insufficient, particularly for the aggressive triple-negative form.
CMTX-101 by Clarametyx Biosciences for Cystic Fibrosis: Likelihood of Approval
Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug
February 20, 2024